Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesLevodopa in the treatment of Parkinson's disease
European Journal of Neurology, 06/17/09
Schapira AHV et al. – A review of levodopa for treatment of Parkinson's disease (PD) summarizes long-term effects, combination treatment, and and primary goals of therapy.
Methods- Review of levodopa for PD treatment
- Predominant motor features of PD caused by degeneration of dopaminergic neurons
- Reversible in part or whole by dopamine replacement or augmentation strategies
- Most experience with use of levodopa; most potent oral dopaminergic treatment for PD
- Long-term use of levodopa may induce motor fluctuations and dyskinesias
- Combination with a catechol-O-methyl transferase inhibitor may be enhance levodopa efficacy and duration
- Primary goals of therapy remain maintaining good motor function and quality of life
- Treatment tailored to individual pt needs is paramount
Related Articles
Widely Used Cholesterol-lowering Drug May Prevent Progression Of Parkinsons Disease
ScienceDaily, 11/10/09
Relevance Score: 70%
Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia
Brain, 10/30/09
Relevance Score: 70%
Effects of optimism/pessimism and locus of control on disability and quality of life in Parkinson's disease
Parkinsonism & Related Disorders, 10/29/09
Relevance Score: 69%
Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS
Parkinsonism & Related Disorders, 10/29/09
Relevance Score: 69%
Condition Raises Parkinsons Risk 5-Fold
Ivanhoe, 10/27/09
Relevance Score: 69%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/05/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/05/09
Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP
Epilepsia, 12/05/09
Sponsor
Article Search
Sponsor